Voriconazole

Phase 1/2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Neutropenia

Conditions

Neutropenia

Trial Timeline

Jun 1, 2003 → Aug 1, 2005

NCT ID

NCT00174473

About Voriconazole

Voriconazole is a phase 1/2 stage product being developed by Pfizer for Neutropenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00174473. Target conditions include Neutropenia.

What happened to similar drugs?

8 of 18 similar drugs in Neutropenia were approved

Approved (8) Terminated (5) Active (8)

✅MicafunginAstellas PharmaApproved

✅Imipenem + ImipenemMerckApproved

✅Ceftolozane-Tazobactam + MeropenemMerckApproved

✅Ceftolozane-tazobactam IVMerckApproved

✅Neulasta (pegfilgrastim)AmgenApproved

✅Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®)Gilead SciencesApproved

✅FilgrastimSandoz GroupApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01092832	Phase 3	Terminated	Oct 1, 2010	Jun 1, 2013	Candidiasis
NCT00836875	Phase 3	Terminated	May 1, 2009	May 1, 2013	Invasive Aspergillosis
NCT00855101	Phase 1	Completed	Apr 1, 2009	Jul 1, 2009	Healthy Volunteers
NCT00721578	Pre-clinical	Completed	Apr 1, 2009	Dec 1, 2009	Systemic Fungal Infections
NCT00556998	Phase 2	Completed	Jun 1, 2008	Dec 1, 2009	Pharmacokinetics
NCT00455364	Approved	Terminated	Apr 1, 2007	Apr 1, 2007	Infection
NCT00300677	Approved	Completed	Mar 1, 2007	Aug 1, 2008	Infections, Fungal
NCT01660334	Pre-clinical	Completed	Jul 1, 2006	May 1, 2012	Scedosporium Infection
NCT01151085	Pre-clinical	Completed	Apr 1, 2006	May 1, 2012	Systemic Mycosis
NCT00288197	Approved	Completed	Jan 1, 2006	Jun 1, 2007	Invasive Fungal Infections
NCT00159822	Phase 2/3	Completed	Jul 1, 2005	Dec 1, 2008	Aspergillosis
NCT00136968	Phase 1	Completed	Apr 1, 2005	May 1, 2005	Fungal Infection
NCT00143312	Approved	Completed	Feb 1, 2005	Apr 1, 2008	Prophylaxis Of Invasive Fungal Infections
NCT00174473	Phase 1/2	Completed	Jun 1, 2003	Aug 1, 2005	Neutropenia
NCT00647907	Approved	Completed	Apr 1, 2003	May 1, 2004	Candidiasis

Competing Products

20 competing products in Neutropenia

See all competitors

Product	Company	Stage	Hype Score
Micafungin	Astellas Pharma	Approved	39
pegfilgrastim	Kyowa Kirin	Phase 2	35
HHPG-19K Injection	Jiangsu Hengrui Medicine	Phase 3	32
caspofungin acetate + Comparator: AmBisome	Merck	Phase 2	35
Imipenem + Imipenem	Merck	Approved	43
Posaconazole IV solution + Posaconazole powder for oral suspension	Merck	Phase 1	29
Ceftolozane-Tazobactam + Meropenem	Merck	Approved	50
Ceftolozane-tazobactam IV	Merck	Approved	35
Daptomycin + Daptomycin	Merck	Phase 3	32
pegfilgrastim	Amgen	Phase 3	40
Neulasta (pegfilgrastim)	Amgen	Approved	43
Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®)	Gilead Sciences	Approved	35
Filgrastim Hospira (US) + US-approved Neupogen®	Pfizer	Phase 1	29
HSP-130 + US-approved Neulasta + EU-approved Neulasta	Pfizer	Phase 1	29
linezolid + vancomycin	Pfizer	Phase 3	40
Anidulafungin	Pfizer	Phase 1/2	32
Nivestim®	Pfizer	Pre-clinical	18
Antibacterial agent for the treatment of febrile neutropenia	Pfizer	Pre-clinical	26
Filgrastim Hospira (US) + U.S.-approved Neupogen®	Pfizer	Phase 1	29
ciprofloxacin + cefepime	Bayer	Phase 3	37